GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AstraZeneca PLC (BUE:AZN) » Definitions » Cyclically Adjusted PS Ratio

AstraZeneca (BUE:AZN) Cyclically Adjusted PS Ratio : 4.71 (As of Jul. 05, 2025)


View and export this data going back to . Start your Free Trial

What is AstraZeneca Cyclically Adjusted PS Ratio?

As of today (2025-07-05), AstraZeneca's current share price is ARS43000.00. AstraZeneca's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was ARS9,124.81. AstraZeneca's Cyclically Adjusted PS Ratio for today is 4.71.

The historical rank and industry rank for AstraZeneca's Cyclically Adjusted PS Ratio or its related term are showing as below:

BUE:AZN' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 2.69   Med: 4.92   Max: 6.78
Current: 4.86

During the past years, AstraZeneca's highest Cyclically Adjusted PS Ratio was 6.78. The lowest was 2.69. And the median was 4.92.

BUE:AZN's Cyclically Adjusted PS Ratio is ranked worse than
77.48% of 737 companies
in the Drug Manufacturers industry
Industry Median: 2.15 vs BUE:AZN: 4.86

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

AstraZeneca's adjusted revenue per share data for the three months ended in Mar. 2025 was ARS9,279.507. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is ARS9,124.81 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


AstraZeneca Cyclically Adjusted PS Ratio Historical Data

The historical data trend for AstraZeneca's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AstraZeneca Cyclically Adjusted PS Ratio Chart

AstraZeneca Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.89 5.51 6.30 5.52 5.02

AstraZeneca Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.45 6.17 5.70 5.02 5.30

Competitive Comparison of AstraZeneca's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - General subindustry, AstraZeneca's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AstraZeneca's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, AstraZeneca's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where AstraZeneca's Cyclically Adjusted PS Ratio falls into.


;
;

AstraZeneca Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

AstraZeneca's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=43000.00/9124.81
=4.71

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AstraZeneca's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, AstraZeneca's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=9279.507/136.1000*136.1000
=9,279.507

Current CPI (Mar. 2025) = 136.1000.

AstraZeneca Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201506 45.303 100.100 61.596
201509 44.187 100.200 60.018
201512 65.472 100.400 88.752
201603 70.596 100.400 95.698
201606 61.920 101.000 83.439
201609 67.149 101.500 90.039
201612 69.934 102.200 93.131
201703 65.821 102.700 87.227
201706 65.783 103.500 86.503
201709 86.193 104.300 112.472
201712 86.860 105.000 112.587
201803 82.345 105.100 106.633
201806 101.473 105.900 130.411
201809 155.096 106.600 198.017
201812 190.965 107.100 242.674
201903 169.277 107.000 215.314
201906 198.297 107.900 250.123
201909 273.066 108.400 342.844
201912 303.375 108.500 380.547
202003 300.372 108.600 376.433
202006 327.179 108.800 409.274
202009 372.219 109.200 463.910
202012 459.273 109.400 571.362
202103 499.913 109.700 620.220
202106 590.805 111.400 721.800
202109 644.851 112.400 780.820
202112 776.563 114.700 921.449
202203 783.451 116.500 915.259
202206 830.817 120.500 938.375
202209 978.800 122.300 1,089.245
202212 1,204.393 125.300 1,308.203
202303 1,377.658 126.800 1,478.701
202306 1,756.308 129.400 1,847.245
202309 2,577.965 130.100 2,696.857
202312 2,780.694 130.500 2,900.019
202403 6,847.473 131.600 7,081.619
202406 7,426.910 133.000 7,600.018
202409 8,254.502 133.500 8,415.264
202412 9,628.624 135.100 9,699.894
202503 9,279.507 136.100 9,279.507

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


AstraZeneca  (BUE:AZN) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


AstraZeneca Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of AstraZeneca's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


AstraZeneca Business Description

Address
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, GBR, CB2 0AA
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.